CD44 and acute myeloid leukemia: This concept was first established in acute myeloid leukemia (AML) [2] and subsequently also in a number of solid tumors such as breast cancer where a CD44+/CD24−/low CSC population was identified [3], in brain tumors [4], colon cancer [5], and melanomas [6].